Cargando…
Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357706/ https://www.ncbi.nlm.nih.gov/pubmed/37463792 http://dx.doi.org/10.1136/jitc-2022-006348corr1 |
Ejemplares similares
-
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023) -
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020) -
Correction: The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
por: Yang, Bin, et al.
Publicado: (2017) -
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022) -
A crucial role for HVEM and BTLA in preventing intestinal inflammation
por: Steinberg, Marcos W., et al.
Publicado: (2008)